


# STEROID USE IN PATIENTS WITH METASTATIC SPINAL CORD COMPRESSION (MSCC)

### THE CHRISTIE, GREATER MANCHESTER & CHESHIRE



(This document is based on material produced by the Edinburgh Cancer Centre)

\*\*O.D. = Once Daily (8am)



\*B.D. = Twice Daily (8am & 2pm)

Dyspepsia/ epigastric pain

Mania/hypomania/psychosis



#### **Appendix**

- Plasma glucose must be checked on all patients commencing steroids.
  Capillary blood glucose testing (CBG) must continue whilst the patient is taking steroids and are an in-patient. CBG testing must continue if patient is discharged if CBG has been elevated as an in-patient. Please refer to local trusts Steroid and CBG monitoring guidance for further information.
- The information below reflects the use of Dexamethasone Injections 4mg in 1ml at The Christie:

There are currently 3 preparations of dexamethasone injection on the UK market. The Organon product (used at The Christie) has been reformulated resulting in changes to its concentration, storage conditions and presentation. In addition the marketing authorisation for the Organon product has now been transferred to Aspen.

As of 1<sup>st</sup> October 2014 there will be no new production of the 4mg/ml product. Therefore when stocks of this are exhausted the only available preparations of Dexamethasone injection will be those made by Aspen and Hamelin/Hospira.

	Aspen	Hameln H	ospira
Dexamethasone	3.8mg/mL	3.3mg/mL	
base (on packaging)			
Volume equivalence	1.05mL ( <b>only 1ml of</b>	1.2mL( <b>only</b>	
of 4mg base	will be available in		each glass
	each glass vial*)	ampoule *)	
Dexamethasone	5.0mg/mL	4.3 mg/mL	
sodium phosphate			
Dexamethasone	Not stated	4.0mg/mL	
phosphate			
Propylene glycol	None	20mg/mL <sup>6</sup> I	None
content			
Storage	Store in a refrigerator	Store below 2	25°C
	(2-8°C)		
Presentation	Glass vial	Glass ampou	le

Following discussion at the Safe Medicines Practice Committee and the Drugs and Therapeutics Committee, we are recommending the following:

- 1. We will procure the Aspen branded product. 3.8mg/ml
- 2. For doses of 4mg Dexamethasone it is acceptable to substitute a dose of 3.8mg.
- 3. For doses of 8mg Dexamethasone it is acceptable to substitute a dose 7 6mg
- 4. For doses of 16mg and above no dose adjustment will be made.





\*For more information and protocols on management of MSCC see: <a href="http://www.christie.nhs.uk/MSCC">http://www.christie.nhs.uk/MSCC</a>

Procedure Reference:		Version:	V4
Document Owner:	Dr V. Misra	Accountable Committee:	Acute Oncology Group Network MSCC Group
Date Approved:	January 2018	Review date:	January 2023
Target audience:	All Clinicians		

# **CONSULTATION, APPROVAL & RATIFICATION PROCESS**

All documents must be involved in a consultation process either locally within a department or division or throughout the trust at relevant board/committee meetings before being submitted for approval.

## **VERSION CONTROL SHEET**

Version	Date	Author	Status	Comment
V1	Jan 2010	Edinburgh	Creation	
		Cancer Centre		
V2	Nov 2013	Vivek Misra	Update	Updated document
		Lena Richards	Review	Reviewed content
V2.1	May 2015	Lena Richards	Update	Updated content
	Jan 2016	Vivek Misra	Review	Reviewed content
V3	Oct 2016	Lena Richards	Update	Appendix added
		Vivek Misra	Review	
		Louise Hopewell	Review	
		Nadia Ali	Review	
V4	Jan 2018	Conor Fitzpatrick	Review	No changes made
	Jan 2020	Nadia Ali	Review	No changes made

